Biotech Values

[DewDiligence]

PTLA, Daiichi Sankyo ink clinical-trial partnership for PRT-4445 and Edoxaban:

http://finance.yahoo.com/news/portola-initiate-phase-2-study-200000190.html

This arrangement is similar to the deals PTLA previously struck for phase-2 testing of PRT-4445 as an antidote for Eliquis (#msg-81069705) and Xarelto (#msg-84232022); no money changes hands, but Daiichi Sankyo will provide Edoxaban free of charge for the phase-2 trial.

Edoxaban, which goes by the brand name Lixiana in Japan, is similar to PTLA’s own FXa inhibitor, Betrixaban, insofar as it’s late to market (except in Japan, where it was approved in 2010 [#msg-48661173]) and it is not well-differentiated from Eliquis and Xarelto.